Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia

Area of Science:

• Neurology
• Neurosurgery
• Movement Disorders

Background:

• Levodopa-induced dyskinesia (LID) is a common complication of Parkinson's disease treatment.
• Deep brain stimulation (DBS) is an established therapy for Parkinson's disease motor symptoms.
• Comparing the efficacy of different DBS targets for LID management is crucial.

Purpose of the Study:

• To compare the effectiveness of subthalamic nucleus (STN) and globus pallidus internus (GPi) DBS in reducing LID.
• To investigate the mechanisms underlying the anti-dyskinetic effects of STN-DBS and GPi-DBS.

Main Methods:

• Retrospective analysis of 43 Parkinson's disease patients with preoperative LID undergoing STN-DBS or GPi-DBS.
• Assessment of changes in Unified Dyskinesia Rating Scale (UDysRS) scores and levodopa equivalent doses.
• Correlation analysis to identify predictors of DBS efficacy for dyskinesia.

Main Results:

• Both STN-DBS and GPi-DBS significantly improved LID, with GPi-DBS showing greater efficacy (93.78% vs. 60.73% UDysRS improvement).
• STN-DBS group achieved a greater reduction in levodopa equivalent dose compared to the GPi-DBS group (43.81% vs. 13.29%).
• LID improvement correlated with levodopa dose reduction in the STN group, but not in the GPi group.

Conclusions:

• Both STN-DBS and GPi-DBS are effective for LID, but GPi-DBS offers superior anti-dyskinetic benefits.
• The anti-dyskinetic effect of STN-DBS may be mediated by a reduction in levodopa dosage.
• GPi-DBS may exert a more direct and independent effect on reducing dyskinesia.